TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32613644

Group type: EXPERIMENTAL
Intervention: Online Acceptance and Commitment Therapy (ACT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioural Therapy (CBT)
Number of subjects: 42
Study: 32118739

Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) therapy, 12 sessions over 3 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acupuncture therapy at specified points using acupuncture needles
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: FSN therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acupuncture therapy
Number of subjects: 80
Study: 35765921

Group type: EXPERIMENTAL
Intervention: 2-g intravenous TXA
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 4-g intravenous TXA
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 33583027

Group type: EXPERIMENTAL
Intervention: Higher dose of dexamethasone (12 mg intravenously daily for up to 10 days)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Lower dose of dexamethasone (6 mg intravenously daily for up to 10 days)
Number of subjects: 1000
Study: 35459949

Group type: EXPERIMENTAL
Intervention: Intracervical insemination (ICI)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Intrauterine insemination (IUI)
Number of subjects: 421
Study: 34376072

Group type: EXPERIMENTAL
Intervention: Correction methods for attrition (specific methods not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulation analyses
Number of subjects: 0
Study: 36200652

Group type: EXPERIMENTAL
Intervention: CART model using PPDU, PPDI, and RGAC as predictors
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: CART model
Number of subjects: 132
Study: 33783488

Group type: EXPERIMENTAL
Intervention: Childhood body size
Number of subjects: 24925

Group type: EXPERIMENTAL
Intervention: Multivariable MR accounting for adult body size
Number of subjects: 24925

Group type: EXPERIMENTAL
Intervention: Childhood body size (specific biomarkers: leucine, isoleucine, tyrosine)
Number of subjects: 24925

Group type: EXPERIMENTAL
Intervention: Very-low-density lipoprotein markers
Number of subjects: 24925
Study: 32291880

Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 521

Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 521
Study: 35477419

Group type: EXPERIMENTAL
Intervention: Guideline & active choice (GA)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Guideline & active choice & action planning (GA +)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Guideline & information (GI)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Physical activity guideline only (control group G)
Number of subjects: 564
Study: 32416983

Group type: EXPERIMENTAL
Intervention: Group 2T10I (screws tightened twice with a 10-minute interval)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2T0I (screws tightened twice with no interval)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 1T (screws tightened 1 time only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group TCT (screws tightened, counter-tightened, and then tightened again)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group TCTCT (screws tightened, counter-tightened, tightened, counter-tightened, and then tightened again)
Number of subjects: 50
Study: 33609498

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer sirolimus-eluting stents (BP SES)
Number of subjects: 5780

Group type: COMPARATOR
Intervention: Durable polymer everolimus-eluting stents (DP EES)
Number of subjects: 5780
Study: 36271193

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment intensity (average 3.7 ± 2.6 equivalent medications at usual dosages)
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system inhibitors
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1431

Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 1431
Study: 32902785

Group type: EXPERIMENTAL
Intervention: Localized sub-Tenon's anesthesia (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Retrobulbar anesthesia (group 2)
Number of subjects: 80
Study: 36082154

Group type: EXPERIMENTAL
Intervention: Handgrip-strengthening exercises (HGSE) added to conventional therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (ultrasound therapy, ice, and stretching exercises)
Number of subjects: 40
Study: 32681996

Group type: EXPERIMENTAL
Intervention: Auto-cross-linked hyaluronic acid gel after surgery
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard care only (control group)
Number of subjects: 272
Study: 34351452

Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy (VMAT) with two small tangential subarcs
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intensity modulated radiotherapy (IMRT) with two tangential fields
Number of subjects: 48
Study: 34053882

Group type: EXPERIMENTAL
Intervention: Spanish version of Patient Satisfaction Questionnaire (PSQ-18)
Number of subjects: 240
Study: 32227754

Group type: EXPERIMENTAL
Intervention: Invasive strategy (initial angiography and revascularization plus guideline‐based medical therapy)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Conservative strategy (guideline‐based medical therapy alone)
Number of subjects: 777
Study: 36071508

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33535795

Group type: EXPERIMENTAL
Intervention: Laminar Airflow System (LAS-OR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional Turbulent Airflow System (CAS-OR)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (LAS and CAS)
Number of subjects: 200
Study: 32750063

Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 100
Study: 34236906

Group type: EXPERIMENTAL
Intervention: Closed-loop haptic IOL (RayOne Trifocal RAO603F IOL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Plate-haptic IOL (AT Lisa tri 839 MP IOL)
Number of subjects: 44
Study: 33002438

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 424

Group type: COMPARATOR
Intervention: Salvage radiotherapy
Number of subjects: 424
Study: 33917433

Group type: EXPERIMENTAL
Intervention: Bench press exercise with 60% one-repetition maximum (1RM) to a 10% decrease of mean bar velocity as a conditioning activity (CA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bench press throw (BPT) with 60% 1RM
Number of subjects: 12
Study: 35688724

Group type: EXPERIMENTAL
Intervention: Erythritol (5 seconds pretreatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium bicarbonate (5 seconds pretreatment)
Number of subjects: 20
Study: 33385417

Group type: EXPERIMENTAL
Intervention: Continuous artificial gravity (cAG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intermittent artificial gravity (iAG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 33030755

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 3833

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3833

Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 3833

Group type: COMPARATOR
Intervention: Etanercept
Number of subjects: 3833
Study: 35667065

Group type: EXPERIMENTAL
Intervention: Molnupiravir, 800 mg, every 12 hours for 5 days
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Molnupiravir
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1433
Study: 34914219

Group type: EXPERIMENTAL
Intervention: Pressing acupuncture therapy (PAT) combined with auricular pressure beans
Number of subjects: 50

Group type: COMPARATOR
Intervention: Auricular pressure beans combined with drug therapy
Number of subjects: 50
Study: 35661487

Group type: EXPERIMENTAL
Intervention: Four-food elimination diet (FFED)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Four-food elimination diet (FFED) + amino acid-based formula (AAF)
Number of subjects: 40
Study: 33400434

Group type: EXPERIMENTAL
Intervention: r-TMS (5 Hz, 20-minute daily session, 5 days per week, for a total of 10 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham r-TMS (same protocol as r-TMS)
Number of subjects: 20
Study: 35379222

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) and exercise intervention, 6 weekly sessions plus one review session after 1 month.
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group received treatment as usual (TAU).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) and exercise intervention.
Number of subjects: 53
Study: 34010359

Group type: EXPERIMENTAL
Intervention: Isometric (ISO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concentric (CON)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eccentric (ECC)
Number of subjects: 10
Study: 32381795

Group type: EXPERIMENTAL
Intervention: Bubble Breath Play Therapy (BBPT)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Tell-Show-Do (TSD) technique
Number of subjects: 48
Study: 35246272

Group type: EXPERIMENTAL
Intervention: Whole-school social marketing intervention including student needs survey, health promotion council, classroom curriculum, social-marketing activities, parent information, and review of sexual health services.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Whole-school social marketing intervention.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Linkage to birth/abortion records.
Number of subjects: 6
Study: 36286651

Group type: COMPARATOR
Intervention: Bulevirtide monotherapy for 24 weeks (MYR202 study)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Bulevirtide monotherapy and combination with PEG‐IFN for 48 weeks (MYR203 study)
Number of subjects: 56
Study: 35395819

Group type: EXPERIMENTAL
Intervention: Core stability training (15 min) + conventional treatment (40 min/day, 5 times/week for 8 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional treatment (40 min/day, 5 times/week for 8 weeks)
Number of subjects: 41
Study: 33639967

Group type: EXPERIMENTAL
Intervention: Tomato powder (30 mg lycopene, 5.38 mg beta-carotene, 22.32 mg phytoene, 9.84 mg phytofluene)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lycopene supplement (30 mg lycopene)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 32479220

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer intervention that paid pregnant women to deliver in a health facility
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditional cash transfer intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 616774602

Group type: EXPERIMENTAL
Intervention: ERAS group (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (n = 50)
Number of subjects: 100
Study: 35318775

Group type: EXPERIMENTAL
Intervention: Execution of the planned behaviour (between-person)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cue detection (within-person)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Execution of the planned behaviour (within-person)
Number of subjects: 90
Study: 32998912

Group type: EXPERIMENTAL
Intervention: Emergency access button (EAB) users
Number of subjects: 217510

Group type: COMPARATOR
Intervention: Normal service (control group)
Number of subjects: 217510
Study: 35648053

Group type: EXPERIMENTAL
Intervention: Interactive video games (IVGs) + traditional neurodevelopment treatment (TNT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Walking training + traditional neurodevelopment treatment (TNT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study: 34264439

Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel in PTEN-low subgroup
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in PTEN-low subgroup
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ipatasertib plus paclitaxel in PIK3CA/AKT1/PTEN-altered subgroup
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel in PIK3CA/AKT1/PTEN-altered subgroup
Number of subjects: 124
Study: 32778083

Group type: EXPERIMENTAL
Intervention: CHAPS intervention (nurse-led care management)
Number of subjects: 140
Study: 34612724

Group type: EXPERIMENTAL
Intervention: Blonanserin tablet (4 to 24 mg/day, orally administered twice daily for 52 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (DB-placebo group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Blonanserin tablet (DB-blonanserin group)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Blonanserin tablet
Number of subjects: 109
Study: 32893428

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 420

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 420
Study: 36052414

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating clinicopathological features and platelet-to-lymphocyte ratio (PLR)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating clinicopathological features and PLR
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 418
Study: 33302270

Group type: EXPERIMENTAL
Intervention: Pomegranate Seed Powder (PSP) 5 g, twice daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 32781371

Group type: EXPERIMENTAL
Intervention: Fostering Changes (FC) training programme
Number of subjects: 312

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 312
Study: 35253582

Group type: EXPERIMENTAL
Intervention: Home-based multimodal physiotherapy intervention (including pain neuroscience education, coping skills training, and therapeutic exercise) with additional supervision
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Home-based multimodal physiotherapy intervention (including pain neuroscience education, coping skills training, and therapeutic exercise) without additional supervision
Number of subjects: 33

Group type: COMPARATOR
Intervention: Usual care (Control group)
Number of subjects: 33
Study: 33326562

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 32416538

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HCV antibody testing by peer outreach workers
Number of subjects: 380

Group type: COMPARATOR
Intervention: Referral to community-based HCV program for testing as usual
Number of subjects: 380
Study: 33726784

Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soy Protein (SP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 35253686

Group type: EXPERIMENTAL
Intervention: Sedentary behavior reduction intervention
Number of subjects: 24
Study: 33999920

Group type: EXPERIMENTAL
Intervention: General anesthesia plus spinal block
Number of subjects: 150

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 150
Study: 34165190

Group type: EXPERIMENTAL
Intervention: Personalized at-home neurofeedback (NF) training
Number of subjects: 178

Group type: COMPARATOR
Intervention: Long-acting methylphenidate (control)
Number of subjects: 178
Study: 33706336

Group type: EXPERIMENTAL
Intervention: Direct breastfeeding program
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (education and counseling on breastfeeding)
Number of subjects: 60
Study: 36156675

Group type: EXPERIMENTAL
Intervention: Citrus and Pomegranate Complex (CPC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 33710587

Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.05% twice daily)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.1% morning, vehicle in the evening)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Topical 17-β-estradiol-3-phosphate eye drops (0.1% twice daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Topical 17-β-estradiol-3-phosphate eye drops and Vehicle
Number of subjects: 104
Study: 35101086

Group type: EXPERIMENTAL
Intervention: Acupuncture therapy combined with fluticasone propionate nasal spray
Number of subjects: 260

Group type: COMPARATOR
Intervention: Fluticasone propionate nasal spray alone
Number of subjects: 260
Study: 33852680

Group type: EXPERIMENTAL
Intervention: Instructional module (palpation prototype and registration guide instrument)
Number of subjects: 68
Study: 33126335

Group type: EXPERIMENTAL
Intervention: Oral fluconazole 800 mg/day for 2 weeks, followed by 400 mg/day for 8 weeks and 200 mg/day for 42 weeks
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Oral fluconazole 400 mg/day for 52 weeks
Number of subjects: 450

Group type: COMPARATOR
Intervention: No antifungal treatment
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study: 36410689

Group type: EXPERIMENTAL
Intervention: PRISM intervention (manualized, brief, skills‐based intervention delivered over 6 months via two 45–60 min one‐on‐one sessions and a family meeting, supplemented by booster calls and a digital app)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 32895269

Group type: EXPERIMENTAL
Intervention: Male involvement during ANC
Number of subjects: 430
Study: 35470200

Group type: EXPERIMENTAL
Intervention: Short video about health apps
Number of subjects: 248

Group type: COMPARATOR
Intervention: Short video about chronic pain
Number of subjects: 248
Study: 33279344

Group type: EXPERIMENTAL
Intervention: Educational peer-group intervention
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 386
Study: 35603772

Group type: EXPERIMENTAL
Intervention: Telehealth mindfulness-based cognitive therapy (MBCT-PD)
Number of subjects: 15
Study: 33465546

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 300 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 34579146

Group type: EXPERIMENTAL
Intervention: Nut consumption (30 g/d of walnuts, almonds, and hazelnuts)
Number of subjects: 0
Study: 33119156

Group type: EXPERIMENTAL
Intervention: Combined impact and resistance training (3 sessions per week for 6 months)
Number of subjects: 47
Study: 35830145

Group type: EXPERIMENTAL
Intervention: DBBM and a collagen membrane
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Bone from tuberosity (TUBER)
Number of subjects: 31
Study: 32725216

Group type: EXPERIMENTAL
Intervention: Daptomycin plus fosfomycin
Number of subjects: 167

Group type: COMPARATOR
Intervention: Daptomycin alone
Number of subjects: 167
Study: 32554737

Group type: EXPERIMENTAL
Intervention: SC +BFI (standard care plus breastfeeding incentives)
Number of subjects: 168

Group type: COMPARATOR
Intervention: SC (standard care control)
Number of subjects: 168
Study: 32766762

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Tofacitinib (overall treatment)
Number of subjects: 1124
Study: 35502595

Group type: EXPERIMENTAL
Intervention: Olympic triathlon
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sprint triathlon
Number of subjects: 15
Study: 34797440

Group type: EXPERIMENTAL
Intervention: Small blood loss (SBL) < 200 ml (n = 404)
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Medium blood loss (MBL) 200 ml ≤ IBL < 400 ml (n = 393)
Number of subjects: 1203

Group type: EXPERIMENTAL
Intervention: Large blood loss (LBL) IBL ≥ 400 ml (n = 406)
Number of subjects: 1203
Study: 34900846

Group type: EXPERIMENTAL
Intervention: Smart watch integrated DIY-CGM
Number of subjects: 60

Group type: COMPARATOR
Intervention: isCGM (usual care)
Number of subjects: 60
Study: 35241003

Group type: EXPERIMENTAL
Intervention: Adjunctive istradefylline (20 mg/day, increasing to 40 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (levodopa-containing medications only)
Number of subjects: 100
Study: 32134464

Group type: EXPERIMENTAL
Intervention: Fluorouracil initiation after surgery
Number of subjects: 10489

Group type: EXPERIMENTAL
Intervention: Erlotinib initiation with gemcitabine
Number of subjects: 10489
Study: 36200674

Group type: EXPERIMENTAL
Intervention: High occupational exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Asthma and COPD coexistence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate exposure with asthma and COPD coexistence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High occupational exposure with asthma and COPD coexistence
Number of subjects: 0
Study: 34460155

Group type: EXPERIMENTAL
Intervention: L-DOPA therapy at the peak
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: L-DOPA therapy at the outcome
Number of subjects: 41
Study: 32232692

Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT) 9.0 g/day
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (no NYT)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ninjin'yoeito (NYT)
Number of subjects: 52
Study: 35863786

Group type: EXPERIMENTAL
Intervention: Ropivacaine (3.75 mg/mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 50
Study: 36240945

Group type: EXPERIMENTAL
Intervention: Symptoms-triggered approach
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fixed-scheduled approach
Number of subjects: 200
Study: 33405340

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (AC50 of 8.9 µM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Proglumetacin (tested twice independently, with AC50 of 8.9 µM and 12.5 µM)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sufugolix (AC50 12.6 µM)
Number of subjects: 42
Study: 32407216

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2, day 1) plus cisplatin (75 mg/m2, day 1)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Vinorelbine (25 mg/m2, days 1 and 8) plus cisplatin (80 mg/m2, day 1)
Number of subjects: 804

Group type: COMPARATOR
Intervention: Vinorelbine plus cisplatin
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin
Number of subjects: 804